Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P00742

UPID:
FA10_HUMAN

ALTERNATIVE NAMES:
Stuart factor; Stuart-Prower factor

ALTERNATIVE UPACC:
P00742; Q14340

BACKGROUND:
The protein Coagulation factor X, known alternatively as Stuart factor or Stuart-Prower factor, plays a pivotal role in the coagulation cascade, converting prothrombin into thrombin. This process is essential for the formation of blood clots, a key component of the body's response to injury.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Coagulation factor X could open doors to potential therapeutic strategies. Its involvement in Factor X deficiency, a disease characterized by bleeding diathesis, positions it as a prime target for developing treatments aimed at enhancing clot formation and preventing excessive bleeding.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.